BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15254428)

  • 21. Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma.
    Wun T; McKnight H; Tuscano JM
    Leuk Res; 2004 Feb; 28(2):179-90. PubMed ID: 14654083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis.
    Zhang DY; Wu J; Ye F; Xue L; Jiang S; Yi J; Zhang W; Wei H; Sung M; Wang W; Li X
    Cancer Res; 2003 Jul; 63(14):4037-43. PubMed ID: 12874003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment.
    Swamy MV; Cooma I; Patlolla JM; Simi B; Reddy BS; Rao CV
    Mol Cancer Ther; 2004 Feb; 3(2):215-21. PubMed ID: 14985462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells.
    Cianchi F; Cortesini C; Magnelli L; Fanti E; Papucci L; Schiavone N; Messerini L; Vannacci A; Capaccioli S; Perna F; Lulli M; Fabbroni V; Perigli G; Bechi P; Masini E
    Mol Cancer Ther; 2006 Nov; 5(11):2716-26. PubMed ID: 17121918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
    Ohtsu N; Takaoka K; Segawa E; Hashitani S; Noguchi K; Kishimoto H; Urade M
    Oncol Rep; 2010 Jul; 24(1):31-6. PubMed ID: 20514441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do elevated levels of eicosanoids play a role in head and neck cancer recurrence and metastasis? Implications for prevention and treatment.
    Cherukuri DP; Nelson MA
    Cancer Biol Ther; 2004 Sep; 3(9):853-4. PubMed ID: 15467420
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor.
    Yoshino T; Kimoto A; Kobayashi S; Noguchi M; Fukunaga M; Hayashi A; Miyata K; Sasamata M
    Arzneimittelforschung; 2005; 55(7):394-402. PubMed ID: 16080279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin.
    Fiorucci S; Distrutti E; Mencarelli A; Morelli A; Laufor SA; Cirino G; Wallace JL
    Br J Pharmacol; 2003 Aug; 139(7):1351-9. PubMed ID: 12890715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
    Gupta S; Adhami VM; Subbarayan M; MacLennan GT; Lewin JS; Hafeli UO; Fu P; Mukhtar H
    Cancer Res; 2004 May; 64(9):3334-43. PubMed ID: 15126378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eicosanoid Diversity of Stony Corals.
    Lõhelaid H; Samel N
    Mar Drugs; 2018 Jan; 16(1):. PubMed ID: 29301345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nimesulide and indomethacin induce apoptosis in head and neck cancer cells.
    Pelzmann M; Thurnher D; Gedlicka C; Martinek H; Knerer B
    J Oral Pathol Med; 2004 Nov; 33(10):607-13. PubMed ID: 15482327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
    Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
    FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
    Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
    Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines.
    Kardosh A; Blumenthal M; Wang WJ; Chen TC; Schönthal AH
    Cancer Biol Ther; 2004 Jan; 3(1):55-62. PubMed ID: 14726653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.
    Waskewich C; Blumenthal RD; Li H; Stein R; Goldenberg DM; Burton J
    Cancer Res; 2002 Apr; 62(7):2029-33. PubMed ID: 11929821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer.
    Freedman RS; Wang E; Voiculescu S; Patenia R; Bassett RL; Deavers M; Marincola FM; Yang P; Newman RA
    Clin Cancer Res; 2007 Oct; 13(19):5736-44. PubMed ID: 17908963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line.
    Liu XH; Kirschenbaum A; Yao S; Stearns ME; Holland JF; Claffey K; Levine AC
    Clin Exp Metastasis; 1999; 17(8):687-94. PubMed ID: 10919714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
    Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
    Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase.
    Kim SH; Kim SH; Song YC; Song YS
    Ann N Y Acad Sci; 2009 Aug; 1171():635-41. PubMed ID: 19723114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways.
    Lippman SM; Gibson N; Subbaramaiah K; Dannenberg AJ
    Clin Cancer Res; 2005 Sep; 11(17):6097-9. PubMed ID: 16144906
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.